Impinj Inc (0J9J.L) Q1 2025 Earnings Report

Impinj reported Q1 2025 revenue of $74.3 million, down 3% year over year and 18.9% quarter over quarter, with a GAAP net loss of $8.45 million and an adjusted EBITDA of $6.5 million (8.7% adjusted EBITDA margin). Gross margin stood at 52.7%, slightly above the prior year but down modestly versus the prior quarter due to mix, while cost discipline kept operating expenses flat at $32.6 million. Endpoint IC revenue totaled $61.2 million and systems revenue $13.1 million, underscoring continued mix shifts toward higher-margin components and reader-related solutions. Management reaffirmed a capability-light at the current macro environment but indicated bookings remained robust and that the tariff backdrop would likely cause a near-term demand wobble, with channel inventory adjustments reflecting geographic optionality rather than an outright demand collapse.

Looking ahead, Impinj provided Q2 guidance calling for revenue between $91 million and $96 million and adjusted EBITDA of $23.5–$26 million, including a license payment that should boost the reported top line. Non-GAAP net income is expected to be about $20.8 million (EPS $0.68–$0.76). Management characterized the guidance as one-quarter-at-a-time and highlighted the M800 ramp and Gen2X-native capabilities as key catalysts for margin expansion and share gains later in 2025. The company also highlighted ongoing enterprise engagements, notably in the grocery and loss-analytics space, and reiterated its view that fixed reading and end-to-end platform adoption remain structural growth drivers.

Overall, Impinj maintains a constructive longer-term growth thesis anchored in its leadership in endpoint ICs, reader ICs, and fixed reading deployments, while navigating a volatile tariff landscape and a near-term demand wobble. The balance sheet remains cash-positive with substantial liquidity, supporting continued R&D and strategic investments, albeit with elevated leverage that investors should monitor as the operating environment evolves.